Introduction: Despite active antiretroviral therapy (ART), community-acquired pneumonia (CAP) remains a major cause of morbidity and mortality among HIVinfected patients, and incurs high health costs.
Introduction
Community-acquired pneumonia (CAP) remains a major complication in human immunodeficiency virus (HIV)-infected patients, even in the era of combined antiretroviral therapy (ART) (1) (2) (3) (4) (5) . Although the introduction of ART has drastically changed the epidemiology of pulmonary infections in HIV-infected patients, not all patients receive ART or show good compliance. In addition, the number of patients with unknown HIV infection remains high.
In 2016, the Global Health Observatory (GHO) reported that 36.7 million people worldwide were living with HIV, almost 21 million people were receiving antiretroviral therapy by mid-2017 and approximately 1 million had died of HIV-related disease (1) .
Progressive CD4+ T-cell loss and changes in immunological status in untreated HIVinfected persons comprise the main risk factors for developing other infectious diseases such as pneumonia, which often require admission to an intensive care unit (ICU)(6).
Several studies have examined the microbial etiology and prognostic factors of CAP in HIV-infected patients (4) (5) (6) . In general, HIV-infected persons have a 10-fold higher risk of developing bacterial pneumonia than HIV-negative persons (7, 8) . However, despite the high rate of bacterial pneumonia in HIV-infected patients, mortality rates are no higher than in patients without HIV infection (5, 9, 10) .
The aim of this article is to review the most recent relevant studies focusing on epidemiology, risk factors, etiology, treatment, prognosis and prevention of CAP in HIV-infected patients.
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Methods
This article reviews the most recent publications relative to Community-Acquired Bacterial Pneumonia in Adult HIV-infected Patients, with a focus on epidemiology, risk factors, microbial etiology, microbiome, antibiotic therapy, prognosis and prevention.
The data discussed in this review were mainly obtained from a non-systematic review using Medline, and references from relevant articles.
Titles and abstracts were initially screened to identify relevant citations, which were then reviewed in full by all authors. All authors confirmed the inclusion of the identified publications.
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Epidemiology
The Global Burden of Disease study (2016) reported that lower respiratory tract infections are the third most common cause of death worldwide, exceeded only by ischemic heart disease and cerebrovascular disease (1) . Similarly, statistics released by the World Health Organization (WHO) in 2015 indicated that 3.2 million of the 56.4 million deaths worldwide in 2015 were caused by lower respiratory tract infections (LRTI), rendering them the most deadly communicable disease and the third leading cause of mortality(11). Bacterial CAP, Pneumocystis infection, and tuberculosis (TB) are the most frequent pulmonary infections in HIV-infected patients(6). The distribution of prevalence of these respiratory infections is associated with specific geographical areas. For example, in low-and middle-income regions, TB remains the main infection related to HIV-infected patients, whereas in high-income regions, bacterial CAP is most frequent in the HIV-infected population.
An interesting study of pneumonia in individuals with and without HIV infection reported that its incidence in HIV-infected patients in the pre-ART era was 5.06 hospitalizations per 100 person-years, compared with 3.46 hospitalizations per 100 person-years in patients without infection. In the post-ART era the incidence was 1.97 hospitalizations per 100 person-years in HIV-infected patients, and 0.59 hospitalizations per 100 person-years in HIV-infected patients with CD4 cell count >500 cell/ul; in patients without HIV infection, it was 0.63 hospitalizations per 100 personyears (12) .
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The use of ART is clearly changing the epidemiology of bacterial CAP in HIV-infected patients. However, HIV infection remains a risk factor for pneumonia even in persons with high CD4+ cell counts.
For example, in an epidemiological study of bacteraemic pneumococcal pneumonia, Grau et al. (13) reported an incidence of 2.41 episodes per 100 patient-years in pre-ART era patients, compared with 0.82 episodes per 100 patient-years in patients with ART.
In an interesting RCT performed in the US (14) , which compared the risk of bacterial pneumonia in HIV-infected patients with intermittent ART therapy and in patients with virologically suppressed HIV infection and receiving continuous ART, the authors reported that HIV-infected patients with predominantly off-ART therapy were over twice as likely to develop bacterial pneumonia (risk rate 2.8 per 100 person-years for those with fewer than 250 CD4 cells) compared with virologically-suppressed HIVinfected patients (risk of 1.0 per 100 person-years for those with 500 or more CD4 cells) in the multivariate analysis.
As with the general population, Streptococcus pneumoniae (pneumococcus) is the main cause of bacterial CAP in HIV-infected patients. Pneumococcus is diagnosed in approximately 30% to 40% of CAP cases in HIV-infected patients with a defined etiology (4, 15) . In a recently published study on lower respiratory tract infection (LRTI) in a cohort of 2669 HIV-infected adults on ART, Lamas et al.(16) reported a LRTI incidence of 3.07 cases/100 patient-years. CAP was diagnosed in 14% (384) of cases.
The same authors also reported that higher CD4 counts and undetectable viral loads were protective factors for CAP in the multivariate analysis, as were pneumococcal and influenza vaccinations. Despite effective ART, bacterial CAP is still frequent in HIV-A c c e p t e d M a n u s c r i p t 8 infected patients(17,18), and mortality rates may be rising due to the prevalence of comorbidities in CAP patients (19) . A prospective study(7) analyzing more than 18,000 patients in 34 countries over the period 2006 to 2011 reported a pneumonia incidence of 0.53 cases/100 person-years. Similarly, in an Italian study, Mussini et al. (20) reported an incidence of bacterial CAP of 0.56 cases/100 person-years.
More recently a study by O'Connor et al. (21) that investigated the effect of immediate initiation of ART on risk of severe bacterial infections in HIV-infected patients with CD4 cell counts >500 cells per ml, and involved intercontinental patient data, reported that the incidence of severe bacterial infection including pneumonia ranges from 0.5 to 2.8 per 100 person-years according to geographical region. Bacterial pneumonia was present in 1.02% of the 4,685 patients: 0.6% of patients who received immediate ART presented bacterial pneumonia whereas 1.44% of patients in whom ART initiation was deferred presented bacterial CAP.
In conclusion, CAP remain a major clinical problem in HIV-infected patients, even though we observed a reduced incidence after ART scale-up, and remains frequent even in HIV-infected patients on ART with high CD4+ cell counts. Overall, HIV-infected patients have a ten times higher risk of developing pneumonia than uninfected patients (19, 22) .
Risk factors for CAP
The specific risk factors for CAP in HIV-infected patients include active and passive smoking, alcoholism, older age (older than 65 years), intravenous drug use, comorbidities (chronic obstructive pulmonary disease, chronic liver disease, cardiovascular disease, chronic renal disease), low CD4 cell counts, detectable HIV viral A c c e p t e d M a n u s c r i p t 9 load, previous episode of pneumonia, and lower socioeconomic status (Table 1) (23) .
The prevalence of smoking in HIV-infected patients in general is very high -between 42% and 46% in US and European studies, compared to 21% to 26% in the general population (24) (25) (26) . Also, excessive alcohol consumption is common among HIVinfected people and increases the risk of pulmonary disease such as pneumonia.
Alcohol affects both innate and adaptive immune responses and causes immunosuppression; this explains why chronic alcohol consumption increases the incidence of bacterial and viral pneumonias in these patients.
A study including data from 34 European countries(7) reported that the factors predisposing HIV-infected patients to develop severe bacterial non-AIDS infections were the presence of previous comorbidities, a previous episode of pneumonia, and malnutrition in the adjusted multivariate analysis.
An American study (27) reported that 10.8% of the approximately 50,000 incident HIV infections that occur annually in the USA affect people ≥50 years old.
Immunosenescence refers to age-related immunological changes that reduce the efficiency of the adaptive and innate immune system, and it is responsible for deterioration in the response to infection and an increase in pathological disorders in the elderly population (28) .
Smoking impacts on the immune system's capacity to mount an appropriate immune and inflammatory response to infections such as CAP, and this effect has also been observed in passive smokers (22, 29, 30) . Some studies have suggested that there is an association between smoking and a poor virological and immunological response to ART (31) (32) (33) (34) . This was confirmed in a recent study by Hile et al.(35) , who studied the M a n u s c r i p t 10 association between tobacco smoking and biomarkers of HIV disease progression, and found that recent tobacco smoking was independently associated with unsuppressed viral load (OR = 1.38) and a low CD4 cell count (OR = 1.12) in multivariate analyses controlling for sociodemographic and clinical characteristics.
It has been reported that approximately 25% of HIV-infected patients have chronic obstructive pulmonary disease (36) . In a recent age and sex-matched study on airway obstruction in 351 HIV-infected and 702 uninfected study participants, all smokers over 40 years of age, the authors found that HIV infection was independently associated with lower FEV1/FVC ratios in a multivariate analysis. They also reported that HIV was associated with an increased prevalence of airway obstruction, as measured by a prebronchodilator FEV1/FVC ratio less than 0.70 and a FEV1 value less than 80% of the theoretical value(37).
In conclusion, the risk factors for CAP in HIV-infected patients are: smoking, alcoholism, advanced age, intravenous drug use, previous comorbidities, low CD4 cell counts, detectable HIV viral load, previous episode of pneumonia, and lower socioeconomic status.
Principal pathogens involved in HIV-infected patients with CAP
Despite advances in microbiological tests, microbial diagnosis is only achieved in approximately 50% of CAP cases. It is known that the bacterial etiology of pneumonia is similar in HIV-infected on ART and in uninfected patients(6,38). In a prospective observational study of 331 consecutive adult CAP cases in HIV-infected patients from jirovecii in the multivariate analysis. In this study HIV infection had been diagnosed prior to hospital admission in 83% of the patients and 51% of the patients were on ART; the remaining 17% of the patients were diagnosed with HIV infection during the pneumonia episode.
In a study from Brazil in which the majority of patients had never used, had abandoned, or reported irregular use of ART, and 73% of patients presented < 200 CD4 cells/mm 3 , the microbial etiology of 224 CAP cases in whom microbial diagnosis was plausible in 64% of cases was as follows (39): Pneumocystis jirovecii was the main agent, detected in 36% of cases, followed by Mycobacterium tuberculosis (20%), S.
pneumoniae and Rhinovirus (15% each), influenza virus (10%), Mycoplasma pneumoniae (8%), and Chlamydophila pneumoniae (5%). The authors also reported The main gram-negative bacterium involved in pneumonia in HIV-infected patients is
Haemophilus influenzae, reported in under 7% of CAP cases in HIV-infected patients(4,6).
Although pneumonia caused by Legionella is more common in patients with immunosuppressive conditions, it is rarely described in HIV-infected patients (44) .
Legionella pneumophila accounts for approximately 20% of all adult HIV-associated pneumonias, compared with 15% in the general population (45) , and most information on this population is based on case reports (46) (47) (48) . In a recent multicenter casecontrol study (32 cases and 96 controls) conducted in Spain on the clinical presentation and outcomes of L. pneumophila CAP, no differences were found in clinical presentation or outcomes between cases and controls. The protective factors identified for developing L. pneumophila pneumonia in HIV-infected patients were undetectable viral load, higher CD4 cell counts, and use of ART in the multivariate analysis(49).
Other intracellular pathogens causing CAP in HIV-infected patients include
Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Coxiella burnetii (45) . A recent study from Portugal of the microbial etiology of CAP in HIV-infected patients reported that M. pneumoniae was responsible for 8% and C. pneumoniae for 7% of CAP cases (39) . Some studies have reported that the pulmonary infection rates of M. In conclusion, the distribution of pathogens in bacterial CAP differs according to the use of ART. Overall, S. pneumoniae, P. jirovecii, H. influenza and respiratory viruses remain the most common pathogens causing CAP in HIV-infected patients.
Microbiome in HIV-infected patients
New culture-independent methods have shown that the lungs, previously thought to be sterile, instead host a diversity of microbial communities collectively known as the Firmicutes, and Natronoanaerobium were common to the oral and airways niche in all patients and included Streptococcus bovis and Chryseobacterium species. These data suggest that HIV-infected patients exhibit a relatively high abundance of a large number of phylogenetically distinct taxa, which include pathogenic organisms, suggesting that recurrent pneumonia in the HIV-infected population may be related to the presence of these species.
In the near future, better knowledge and understanding of the lung (and gut) microbiome will shed light on the physiopathology, treatment, and prevention of CAP.
Assessment of severity and making site-of-care decisions
Several instruments such as the Pneumonia Severity Index (PSI) and the CURB-65 (42), which analyzed the association between nasopharyngeal S. pneumoniae densities in HIV-infected patients from South Africa with markers of severity and poor outcomes, reported no correlation between CURB-65 and mortality in these patients. However, the study by Almeida et al. (62) investigated the use of CURB65 in HIV-infected patients, and reported that a higher A c c e p t e d M a n u s c r i p t 17 CURB65 score and a CD4 count lower than 200 cells/mL were both associated with worse outcomes. They concluded that the CURB65 score plus CD4 cell count could be used in HIV-infected patients with CAP.
In conclusion, the combined use of severity scores such as PSI or CURB65 and CD4 cell count should help clinicians to determine the severity of bacterial CAP in HIV-infected patients ( Figure 2 ).
Antibiotic therapy
Antibiotic therapy in HIV-infected patients with CAP does not differ significantly from that administered to the general population. Nevertheless, current pneumonia guidelines do not specifically include the HIV-infected population (60, 63) , suggesting that treatment should be similar to that for the general population. Although HIVinfected patients on ART show an improved immune response, CD4 reconstitution, and viral suppression, these patients are still at higher risk of pneumonia in part because they show altered immunity and because immune activation persists even when receiving ART(7).
The empiric antibiotic therapy for CAP should cover the main pathogens that cause pneumonia, including S. pneumoniae and intracellular bacteria (C. pneumoniae, C. In contrast, a prospective observational international multicenter study that included 844 adult HIV-infected and uninfected patients with pneumococcal bacteremia found that combination therapy was associated with a lower 14-day mortality rate in only severely ill patients (23% versus 55%; p = 0.015)(65) but there were no significant differences between the two groups. A potential explanation for these results is the fact that macrolides not only inhibit bacterial protein synthesis, but are also potent inhibitors of the production of pneumolysin and reduce the adherence of pneumococcus to respiratory epithelium.
In regions where M. tuberculosis is common we must exercise caution regarding fluoroquinolone monotherapy, since its use in M. tuberculosis cases may render the A c c e p t e d M a n u s c r i p t 19 sputum culture negative due to the rapid clearance of the pathogen in the sputum sample and the development of fluoroquinolone resistance in the isolates.
Drug interactions between ART and CAP antibiotic therapy
Drug-drug interactions (DDI) present significant risks to patients and are a challenge for health care providers. However, there is no interaction between ART families and penicillins, beta-lactams inhibitors or levofloxacin. Moxifloxacin has a low interaction with atazanavir and lopinavir (protease inhibitors): it has been shown to prolong the QT interval, and so care should be taken especially in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances, and so on).
Azithromycin may cause abnormal changes in the electrical activity of the heart and can induced QTc interval prolongation and Torsade de pointes. This adverse event should be taken into account when antiretrovirals can increase its exposure (like ritonavir-boosted protease inhibitors) or can also increase QT interval (rilpivirine).
Azithromycin is mainly eliminated via biliary excretion and animal data suggest this may occur via P-glycoprotein and MRP2. Ritonavir-boosted regimens could potentially increase azithromycin exposure (inhibition of P-glycoprotein and MRP2); however, no a priori dosage adjustment is recommended for azithromycin. Cobicistat is not expected to inhibit hepatic P-gp and MRP2 at clinically relevant concentrations and can be given concomitantly with azithromycin. Rilpivirine (an NNRTIs drug) should be used with caution when co administered with a drug with a known risk of Torsade de
Pointes. In healthy subjects, supra-therapeutic doses of rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QTc interval. We recommend these two links for more updated information on DDI between the antimicrobials used to treat pulmonary infections and antiretroviral drugs:
https://www.hiv-druginteractions.org/checker (English Web site);
http://www.interaccionesvih.com/interaccions.html (Spanish Web site)
Prognosis of Bacterial CAP in HIV-infected patients
In a recent study of 806 patients admitted to the medical and surgical ICUs at Groote Schuur Hospital, Cape Town, South Africa over the course of one year (66), 77 were HIV-positive (9.6%), and the main cause of ICU admission was CAP. The same authors reported that ICU mortality was 25% and hospital mortality was 35%. These data clearly demonstrate that CAP is a major cause of morbidity and mortality among HIVinfected persons, especially in those not receiving ART -a very frequent situation in the geographical region where this study was conducted.
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Bacterial CAP mortality in HIV-infected patients in the post-ART era has been reported to range between 6% and 15% (4,7). Despite the high rate of bacterial pneumonia in HIV-infected patients, mortality rates are not higher than in non-HIV-infected patients (5, 10, 19, 67) . The risk factors reported associate with higher mortality are neutropenia, a CD4 cell count of < 100 cells per mm 3 , a Karnofsky score of ≤ 50, LDH ≥ 598 U/L, mechanical ventilation, a partial pressure of oxygen < 70 mmHg, shock, and radiographic progression of disease (4, 19, 38) .
In a retrospective study from Italy, the authors studied 84 bacterial CAP episodes in 76
HIV-infected inpatients. The proportion of patients receiving ART was 42% whereas 58% of HIV-infected patients were not treated. Although the time to clinical stability was longer in patients without ART (1.9 ± 7.9 vs. 7.6 ± 5.4 days; p = 0.01), the author did not observe differences in mortality between HIV-infected patients with or without ART (44% vs. 55%) because of the small sample size (19) .
In a case-control study from the USA that aimed to determine differences in clinical outcomes between hospitalized HIV-positive and HIV-negative patients with CAP, 
Conclusions
Community-acquired pneumonia in HIV-infected patients is a major cause of morbidity, and mortality. However, the management and outcomes of bacterial CAP in HIV-infected persons on ART are similar to those in uninfected persons, suggesting that the management should be the same for both populations.
Expert commentary
Recent studies have reported that despite ART, bacterial CAP remains a major cause of disease, health costs, and mortality in the HIV-infected population, especially in highincome countries. However, in middle and low-income countries tuberculosis remains is not yet available to millions of HIV-infected people, especially in developing countries.
Since pneumococcal pneumonia is the most frequently occurring bacterial infection in HIV-infected persons on ART and is associated with higher mortality rates, preventive strategies such as smoking cessation programs and vaccination campaigns are essential. Also, we recommend that since HIV is diagnosed in many cases of CAP, all suspected cases of CAP should be tested for HIV.
Early identification of HIV infection is mandatory, especially in those geographical areas most affected by this pandemic, in order to start effective ART therapy and improve the quality of life of affected persons.
Five-year view
CAP in the HIV-infected population is a major health problem worldwide. Since HIVinfected patients are surviving longer than those who were ill before the advent of ART, we will observe changes in the epidemiology of CAP. In future clinical practice, multidisciplinary specialist teams will be required for the management of HIV-infected 
Key issues
• Despite ART, bacterial pneumonia remains a major cause of disease in the HIVinfected population.
• Streptococcus pneumoniae is the most frequently detected pathogen causing bacterial CAP in HIV-infected patients on ART. Tuberculosis and Pneumocystis infection are the prevalent pathogens in geographical areas with a lower rate of HIV diagnosis and no ART therapy.
• The clinical presentation and management of bacterial CAP is similar in HIVinfected patients on ART and uninfected patients.
• In HIV virologically suppressed patients on ART with > 350 CD4+ T-cell count/mm 3 clinical outcomes are similar to the general population. We recommend that such patients do not need treatment, admission, or care sites that differs from that of the general population.
• Bacterial CAP prevention measures such as smoking cessation and vaccination campaigns are crucial in the HIV-infected population. 
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